

MEMORANDUM

TO: California Office of Statewide Health Planning and Development
FROM: Cipla USA, Inc.
DATE: April 1, 2019
RE: Quarterly Price Increase Reporting

Cipla USA, Inc. hereby submits its quarterly price increase reporting pursuant to Cal. Health & Safety Code § 127679(a). Effective March 4, 2019, Cipla increased the wholesale acquisition cost (“WAC”) of its calcium acetate tablet from \$90.97 to \$120.00 due to an increase in API cost. This is the sole increase in the last five years. *See Calcium Acetate Tablet WAC Schedule.* This product is a non-innovator multiple source drug product. There are no unexpired patents listed for this product in FDA’s *Approved Drug Products with Therapeutic Equivalence Evaluations* database (commonly known as the Orange Book). In the last year, Cipla sold 9,394,000 extended units of calcium acetate in the United States.

Calcium Acetate Tablet WAC History
NDC 69097-0862-83

WAC	Effective Date
\$133.00	November 1, 2015
\$90.97	November 7, 2017
\$120.00	March 4, 2019